Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
Non-small cell lung cancer (NSCLC) is one of the world’s leading causes of morbidity and mortality. ICIs alone or combined with chemotherapy have become the standard first-line treatment of metastatic NSCLC. The impressive results obtained have stimulated our interest in applying these therapies in...
Main Authors: | Guillermo Suay, Juan-Carlos Garcia-Cañaveras, Francisco Aparisi, Agustin Lahoz, Oscar Juan-Vidal |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/18/4433 |
Similar Items
-
Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
by: Lavinia Gatteschi, et al.
Published: (2021-10-01) -
Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
by: Virginia Ferraresi, et al.
Published: (2022-05-01) -
A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer
by: Zhuo Chen, et al.
Published: (2024-06-01) -
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2023-02-01) -
Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
by: Yutaka Takahara, et al.
Published: (2023-09-01)